Literature DB >> 11711678

Tumor therapy with targeted atomic nanogenerators.

M R McDevitt1, D Ma, L T Lai, J Simon, P Borchardt, R K Frank, K Wu, V Pellegrini, M J Curcio, M Miederer, N H Bander, D A Scheinberg.   

Abstract

A single, high linear energy transfer alpha particle can kill a target cell. We have developed methods to target molecular-sized generators of alpha-emitting isotope cascades to the inside of cancer cells using actinium-225 coupled to internalizing monoclonal antibodies. In vitro, these constructs specifically killed leukemia, lymphoma, breast, ovarian, neuroblastoma, and prostate cancer cells at becquerel (picocurie) levels. Injection of single doses of the constructs at kilobecquerel (nanocurie) levels into mice bearing solid prostate carcinoma or disseminated human lymphoma induced tumor regression and prolonged survival, without toxicity, in a substantial fraction of animals. Nanogenerators targeting a wide variety of cancers may be possible.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11711678     DOI: 10.1126/science.1064126

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  120 in total

1.  Alpha particles induce apoptosis through the sphingomyelin pathway.

Authors:  Jonathan H Seideman; Branka Stancevic; Jimmy A Rotolo; Michael R McDevitt; Roger W Howell; Richard N Kolesnick; David A Scheinberg
Journal:  Radiat Res       Date:  2011-06-01       Impact factor: 2.841

Review 2.  An overview of targeted alpha therapy.

Authors:  Young-Seung Kim; Martin W Brechbiel
Journal:  Tumour Biol       Date:  2011-12-06

3.  In vitro evaluation of 213Bi-rituximab versus external gamma irradiation for the treatment of B-CLL patients: relative biological efficacy with respect to apoptosis induction and chromosomal damage.

Authors:  Katia Vandenbulcke; Filip De Vos; Fritz Offner; Jan Philippé; Christos Apostolidis; Roger Molinet; Tuomo K Nikula; Klaus Bacher; Virginie de Gelder; Anne Vral; Christophe Lahorte; Hubert Thierens; Rudi A Dierckx; Guido Slegers
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-07-03       Impact factor: 9.236

4.  Noncovalent scFv multimers of tumor-targeting anti-Lewis(y) hu3S193 humanized antibody.

Authors:  Barbara E Power; Larissa Doughty; Deborah R Shapira; John E Burns; Ann M Bayly; Joanne M Caine; Zhanqi Liu; Andrew M Scott; Peter J Hudson; Alexander A Kortt
Journal:  Protein Sci       Date:  2003-04       Impact factor: 6.725

5.  Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization.

Authors:  Daniel J Nolan; Alessia Ciarrocchi; Albert S Mellick; Jaspreet S Jaggi; Kathryn Bambino; Sunita Gupta; Emily Heikamp; Michael R McDevitt; David A Scheinberg; Robert Benezra; Vivek Mittal
Journal:  Genes Dev       Date:  2007-06-15       Impact factor: 11.361

Review 6.  Therapeutic radionuclides: biophysical and radiobiologic principles.

Authors:  Amin I Kassis
Journal:  Semin Nucl Med       Date:  2008-09       Impact factor: 4.446

7.  Novel bimodal bifunctional ligands for radioimmunotherapy and targeted MRI.

Authors:  Hyun-Soon Chong; Hyun A Song; Xiang Ma; Diane E Milenic; Erik D Brady; Sooyoun Lim; Haisung Lee; Kwamena Baidoo; Dengfeng Cheng; Martin W Brechbiel
Journal:  Bioconjug Chem       Date:  2008-06-20       Impact factor: 4.774

8.  MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy.

Authors:  George Sgouros; John C Roeske; Michael R McDevitt; Stig Palm; Barry J Allen; Darrell R Fisher; A Bertrand Brill; Hong Song; Roger W Howell; Gamal Akabani; Wesley E Bolch; A Bertrand Brill; Darrell R Fisher; Roger W Howell; Ruby F Meredith; George Sgouros; Barry W Wessels; Pat B Zanzonico
Journal:  J Nucl Med       Date:  2010-01-15       Impact factor: 10.057

9.  Leveraging Bioorthogonal Click Chemistry to Improve 225Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma.

Authors:  Sophie Poty; Lukas M Carter; Komal Mandleywala; Rosemery Membreno; Dalya Abdel-Atti; Ashwin Ragupathi; Wolfgang W Scholz; Brian M Zeglis; Jason S Lewis
Journal:  Clin Cancer Res       Date:  2018-10-23       Impact factor: 12.531

Review 10.  Peptide-targeted radionuclide therapy for melanoma.

Authors:  Yubin Miao; Thomas P Quinn
Journal:  Crit Rev Oncol Hematol       Date:  2008-04-02       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.